Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.1 passage
• 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial.1 passage
• A clinical approach to diagnosis of autoimmune encephalitis.1 passage
• A roadmap for precision medicine in the epilepsies.1 passage
• A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial.1 passage
• APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.1 passage
• Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data.1 passage
• Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.1 passage
• Accelerating stem cell trials for Alzheimer's disease.1 passage
• Adaptation of neurological practice and policy to a changing US health-care landscape.1 passage
• Advances and challenges in stroke rehabilitation.1 passage
• Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia.1 passage
• Advances in management of movement disorders in children.1 passage
• Advances in neuroimaging to improve care in sickle cell disease.1 passage
• Advances in oral immunomodulating therapies in relapsing multiple sclerosis.1 passage
• Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.1 passage
• Advances in the development of biomarkers for epilepsy.1 passage
• Advances in the diagnosis and treatment of fungal infections of the CNS.1 passage
• Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development.1 passage
• Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies.1 passage
• Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.1 passage
• Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.1 passage
• Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?1 passage
• Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.1 passage
• Alzheimer's disease associated with Down syndrome: a genetic form of dementia.1 passage
• Amantadine in the treatment of Parkinson's disease and other movement disorders.1 passage
• Amyloid-PET and1 passage
• Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism.1 passage
• Amyotrophic lateral sclerosis: moving towards a new classification system.1 passage
• An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration.1 passage
• An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models.1 passage
• Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial.1 passage
• Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies.1 passage
• Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial.1 passage
• Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment.1 passage
• Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial.1 passage
• Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.1 passage
• Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.1 passage
• Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial.1 passage
• Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis.1 passage
• Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.1 passage
• Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study.1 passage
• Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.1 passage
• Association between circadian rhythms and neurodegenerative diseases.1 passage
• Association between pathological and MRI findings in multiple sclerosis.1 passage
• Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study.1 passage
• Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study.1 passage
• Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study.1 passage
• Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.1 passage
• Atypical inflammatory demyelinating syndromes of the CNS.1 passage
• Axon guidance proteins in neurological disorders.1 passage
• B vitamins in stroke prevention: time to reconsider.1 passage
• BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.1 passage
• Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.1 passage
• Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial.1 passage
• Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.1 passage
• Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.1 passage
• Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.1 passage
• Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.1 passage
• Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.1 passage
• Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.1 passage
• Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.1 passage
• Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data.1 passage
• Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.1 passage
• Brain imaging in the assessment for epilepsy surgery.1 passage
• Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation.1 passage
• Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches.1 passage
• Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.1 passage
• C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis.1 passage
• CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study.1 passage
• CSF and blood biomarkers for Parkinson's disease.1 passage
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.1 passage
• Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.1 passage
• Carpal tunnel syndrome: clinical features, diagnosis, and management.1 passage
• Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study.1 passage
• Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances.1 passage
• Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study.1 passage
• Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies.1 passage
• Cerebrovascular function in presymptomatic and symptomatic individuals with hereditary cerebral amyloid angiopathy: a case-control study.1 passage
• Challenges in the diagnosis of Parkinson's disease.1 passage
• Challenges of modifying disease progression in prediagnostic Parkinson's disease.1 passage
• Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series.1 passage
• Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study.1 passage
• Circadian and circaseptan rhythms in human epilepsy: a retrospective cohort study.1 passage
• Circadian rhythm and epilepsy.1 passage
• Classification and management of adult inflammatory myopathies.1 passage
• Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.1 passage
• Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.1 passage
• Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis.1 passage
• Clinical application of next-generation sequencing to the practice of neurology.1 passage
• Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.1 passage
• Clinical characteristics and outcomes in patients with traumatic brain injury in China: a prospective, multicentre, longitudinal, observational study.1 passage
• Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data.1 passage
• Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.1 passage
• Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.1 passage
• Clinical presentation and management of dyskinetic cerebral palsy.1 passage
• Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder.1 passage
• Clinical presentation, management, and pathophysiology of neuropathic itch.1 passage
• Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.1 passage
• Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.1 passage
• Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management.1 passage
• Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.1 passage
• Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.1 passage
• Cognitive function in patients with diabetes mellitus: guidance for daily care.1 passage
• Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues.1 passage
• Comorbidities of epilepsy: current concepts and future perspectives.1 passage
• Comorbidities, treatment, and pathophysiology in restless legs syndrome.1 passage
• Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.1 passage
• Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.1 passage
• Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.1 passage
• Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I).1 passage
• Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.1 passage
• Constraint-induced movement therapy after stroke.1 passage
• Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.1 passage
• Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study.1 passage
• Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.1 passage
• Cranial functional (psychogenic) movement disorders.1 passage
• DNA repair in the trinucleotide repeat disorders.1 passage
• DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.1 passage
• Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.1 passage
• Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data.1 passage
• Dementia in China: epidemiology, clinical management, and research advances.1 passage
• Dementia in Down's syndrome.1 passage
• Dementia in western Europe: epidemiological evidence and implications for policy making.1 passage
• Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study.1 passage
• Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.1 passage
• Detection, risk factors, and functional consequences of cerebral microinfarcts.1 passage
• Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis.1 passage
• Development of epilepsy after ischaemic stroke.1 passage
• Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies.1 passage
• Diagnosis and assessment of neuropathic pain through questionnaires.1 passage
• Diagnosis and clinical features of common optic neuropathies.1 passage
• Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.1 passage
• Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.1 passage
• Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan.1 passage
• Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.1 passage
• Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis.1 passage
• Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression.1 passage
• Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.1 passage
• Diagnosis, pathophysiology, and management of cluster headache.1 passage
• Diagnosis, prognosis, and clinical management of mild traumatic brain injury.1 passage
• Diagnosis, prognosis, and treatment of leukodystrophies.1 passage
• Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study.1 passage
• Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study.1 passage
• Diagnostic challenges in epilepsy: seizure under-reporting and seizure detection.1 passage
• Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders.1 passage
• Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.1 passage
• Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial.1 passage
• Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis.1 passage
• Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study.1 passage
• Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN).1 passage
• Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.1 passage
• Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data.1 passage
• Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.1 passage
• Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.1 passage
• Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.1 passage
• Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.1 passage
• Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data.1 passage
• Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.1 passage
• Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.1 passage
• Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.1 passage
• Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial.1 passage
• Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial.1 passage
• Efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation (EVREST): a randomised, multicentre, single-blind, controlled trial.1 passage
• Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.1 passage
• Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.1 passage
• Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.1 passage
• Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.1 passage
• End-of-life management in patients with amyotrophic lateral sclerosis.1 passage
• Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke.1 passage
• Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial.1 passage
• Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.1 passage
• Epidemiology, aetiology, and management of ischaemic stroke in young adults.1 passage
• Epidemiology, pathophysiology, diagnosis, and management of intracranial artery dissection.1 passage
• Epigenetics of dementia: understanding the disease as a transformation rather than a state.1 passage
• Epilepsy genetics: clinical impacts and biological insights.1 passage
• Epilepsy in China: major progress in the past two decades.1 passage
• Epileptic activity in Alzheimer's disease: causes and clinical relevance.1 passage
• Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.1 passage
• Essential tremor-plus: a controversial new concept.1 passage
• Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.1 passage
• Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study.1 passage
• Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.1 passage
• Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person-environment fit.1 passage
• Exercise in patients with multiple sclerosis.1 passage
• Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study.1 passage
• Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study.1 passage
• Forecasting seizure risk in adults with focal epilepsy: a development and validation study.1 passage
• Freezing of gait: a practical approach to management.1 passage
• Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.1 passage
• Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.1 passage
• Functional MRI of migraine.1 passage
• Functional outcomes of pre-hospital thrombolysis in a mobile stroke treatment unit compared with conventional care: an observational registry study.1 passage
• Future directions of acute ischaemic stroke therapy.1 passage
• Gadolinium deposition in the brain: summary of evidence and recommendations.1 passage
• Gait impairments in Parkinson's disease.1 passage
• Gastrointestinal dysfunction in Parkinson's disease.1 passage
• Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study.1 passage
• Gene hunting in autism spectrum disorder: on the path to precision medicine.1 passage
• Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.1 passage
• Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies.1 passage
• Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.1 passage
• Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond.1 passage
• Global brain inflammation in stroke.1 passage
• Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.1 passage
• Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.1 passage
• Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.1 passage
• Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.1 passage
• Harnessing the integrated stress response for the treatment of multiple sclerosis.1 passage
• Headache arising from idiopathic changes in CSF pressure.1 passage
• Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.1 passage
• Heart health meets cognitive health: evidence on the role of blood pressure.1 passage
• Heat shock proteins as potential targets for protective strategies in neurodegeneration.1 passage
• Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches.1 passage
• Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF1 passage
• Home-based constraint-induced movement therapy for patients with upper limb dysfunction after stroke (HOMECIMT): a cluster-randomised, controlled trial.1 passage
• Hypocretin (orexin) biology and the pathophysiology of narcolepsy with cataplexy.1 passage
• Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies.1 passage
• Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.1 passage
• Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study.1 passage
• Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis.1 passage
• Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies.1 passage
• Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions.1 passage
• IgG4-related disease of the central and peripheral nervous systems.1 passage
• Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications.1 passage
• Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data.1 passage
• Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies.1 passage
• Impaired consciousness in patients with absence seizures investigated by functional MRI, EEG, and behavioural measures: a cross-sectional study.1 passage
• Implications of sleep disturbance and inflammation for Alzheimer's disease dementia.1 passage
• Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.1 passage
• In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study.1 passage
• Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study.1 passage
• Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study.1 passage
• Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects.1 passage
• Increasing value and reducing waste in stroke research.1 passage
• Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis.1 passage
• Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke.1 passage
• Initiation of pharmacological therapy in Parkinson's disease: when, why, and how.1 passage
• Innate and adaptive immune responses in the CNS.1 passage
• Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease.1 passage
• Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management.1 passage
• Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care.1 passage
• Interpretation of risk loci from genome-wide association studies of Alzheimer's disease.1 passage
• Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.1 passage
• Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.1 passage
• Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study.1 passage
• Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.1 passage
• Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project.1 passage
• Is a separate monotherapy indication warranted for antiepileptic drugs?1 passage
• LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.1 passage
• Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.1 passage
• Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.1 passage
• Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.1 passage
• Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.1 passage
• Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.1 passage
• Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.1 passage
• Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data.1 passage
• Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial.1 passage
• Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.1 passage
• Long-term unsupervised mobility assessment in movement disorders.1 passage
• Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.1 passage
• Lower urinary tract dysfunction in the neurological patient: clinical assessment and management.1 passage
• Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus (SINPHONI-2): an open-label randomised trial.1 passage
• MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.1 passage
• MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.1 passage
• MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers.1 passage
• MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis.1 passage
• Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study.1 passage
• Management of epilepsy in women.1 passage
• Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.1 passage
• Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.1 passage
• Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities.1 passage
• Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised controlled trial.1 passage
• Menstrual migraine: a distinct disorder needing greater recognition.1 passage
• MicroRNAs in epilepsy: pathophysiology and clinical utility.1 passage
• Migraine and the trigeminovascular system-40 years and counting.1 passage
• Migraine pathophysiology: lessons from mouse models and human genetics.1 passage
• Mitochondrial disease in adults: recent advances and future promise.1 passage
• Mitochondrial dysfunction and seizures: the neuronal energy crisis.1 passage
• Mobile stroke units for prehospital thrombolysis, triage, and beyond: benefits and challenges.1 passage
• Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial.1 passage
• Monogenic variants in dystonia: an exome-wide sequencing study.1 passage
• Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection.1 passage
• Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson's disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study.1 passage
• Music-based interventions in neurological rehabilitation.1 passage
• Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study.1 passage
• Myasthenia gravis: subgroup classification and therapeutic strategies.1 passage
• Myelin-oligodendrocyte glycoprotein antibody-associated disease.1 passage
• Natural history of multiple system atrophy in the USA: a prospective cohort study.1 passage
• Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours.1 passage
• Network imaging biomarkers: insights and clinical applications in Parkinson's disease.1 passage
• Neural correlates of consciousness in patients who have emerged from a minimally conscious state: a cross-sectional multimodal imaging study.1 passage
• Neurocognitive factors in sensory restoration of early deafness: a connectome model.1 passage
• Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.1 passage
• Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.1 passage
• Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan.1 passage
• Neuroinflammation in Alzheimer's disease.1 passage
• Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation.1 passage
• Neurological and neuropsychiatric aspects of tuberous sclerosis complex.1 passage
• Neurological associations of COVID-19.1 passage
• Neurological consequences of obesity.1 passage
• Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study.1 passage
• Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).1 passage
• Neurological prognostication of outcome in patients in coma after cardiac arrest.1 passage
• Neuromodulation in epilepsy: state-of-the-art approved therapies.1 passage
• Neuromodulation in the restoration of function after spinal cord injury.1 passage
• Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.1 passage
• Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.1 passage
• Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation.1 passage
• New evidence on the management of Lewy body dementia.1 passage
• New insights into atypical Alzheimer's disease in the era of biomarkers.1 passage
• New therapeutic approaches for the prevention and treatment of migraine.1 passage
• New therapies for neuromyelitis optica spectrum disorder.1 passage
• Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.1 passage
• Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.1 passage
• Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.1 passage
• Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.1 passage
• Nutrition and prevention of cognitive impairment.1 passage
• Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?1 passage
• Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.1 passage
• Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.1 passage
• Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.1 passage
• Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.1 passage
• PET imaging of neuroinflammation in neurological disorders.1 passage
• Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care.1 passage
• Paediatric stroke: pressing issues and promising directions.1 passage
• Pain in amyotrophic lateral sclerosis.1 passage
• Palliative care in amyotrophic lateral sclerosis.1 passage
• Parkinson's disease in the Western Pacific Region.1 passage
• Parkinson's disease outside the brain: targeting the autonomic nervous system.1 passage
• Paroxysmal sympathetic hyperactivity: the storm after acute brain injury.1 passage
• Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.1 passage
• Pathological mechanisms in progressive multiple sclerosis.1 passage
• Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia.1 passage
• Pathophysiology, prevention, and treatment of medication overuse headache.1 passage
• Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data.1 passage
• Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.1 passage
• Pharyngeal electrical stimulation for early decannulation in tracheotomised patients with neurogenic dysphagia after stroke (PHAST-TRAC): a prospective, single-blinded, randomised trial.1 passage
• Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.1 passage
• Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.1 passage
• Pisa syndrome in Parkinson's disease and parkinsonism: clinical features, pathophysiology, and treatment.1 passage
• Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.1 passage
• Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study.1 passage
• Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.1 passage
• Pleiotropic genetic effects influencing sleep and neurological disorders.1 passage
• Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment.1 passage
• Post-viral effects of COVID-19 in the olfactory system and their implications.1 passage
• Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.1 passage
• Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study.1 passage
• Potential human transmission of amyloid β pathology: surveillance and risks.1 passage
• Prediagnostic presentations of Parkinson's disease in primary care: a case-control study.1 passage
• Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.1 passage
• Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.1 passage
• Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study.1 passage
• Prediction of motor recovery after stroke: advances in biomarkers.1 passage
• Prehospital stroke management in the thrombectomy era.1 passage
• Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial.1 passage
• Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.1 passage
• Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis.1 passage
• Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study.1 passage
• Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.1 passage
• Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.1 passage
• Priorities to reduce the burden of stroke in Latin American countries.1 passage
• Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.1 passage
• Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.1 passage
• Progress towards therapies for disease modification in Parkinson's disease.1 passage
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.1 passage
• Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study.1 passage
• Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.1 passage
• Rare coding variants in genes encoding GABA1 passage
• Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.1 passage
• Recent developments in drug-induced movement disorders: a mixed picture.1 passage
• Reflex seizures, traits, and epilepsies: from physiology to pathology.1 passage
• Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.1 passage
• Remyelination in multiple sclerosis: from basic science to clinical translation.1 passage
• Research priorities to reduce the global burden of dementia by 2025.1 passage
• Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial.1 passage
• Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.1 passage
• Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.1 passage
• Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.1 passage
• Risk factors for non-motor symptoms in Parkinson's disease.1 passage
• Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.1 passage
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.1 passage
• Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis.1 passage
• Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.1 passage
• Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.1 passage
• Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Role of the innate and adaptive immune responses in the course of multiple sclerosis.1 passage
• Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.1 passage
• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.1 passage
• Safety and efficacy of GABA1 passage
• Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.1 passage
• Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.1 passage
• Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.1 passage
• Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.1 passage
• Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.1 passage
• Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.1 passage
• Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.1 passage
• Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.1 passage
• Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study.1 passage
• Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.1 passage
• Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial.1 passage
• Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial.1 passage
• Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.1 passage
• Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.1 passage
• Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.1 passage
• Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study.1 passage
• Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.1 passage
• Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.1 passage
• Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.1 passage
• Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial.1 passage
• Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial.1 passage
• Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.1 passage
• Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial.1 passage
• Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial.1 passage
• Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.1 passage
• Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.1 passage
• Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.1 passage
• Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial.1 passage
• Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.1 passage
• Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.1 passage
• Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.1 passage
• Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.1 passage
• Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial.1 passage
• Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.1 passage
• Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.1 passage
• Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial.1 passage
• Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.1 passage
• Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.1 passage
• Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.1 passage
• Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.1 passage
• Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.1 passage
• Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.1 passage
• Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.1 passage
• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.1 passage
• Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.1 passage
• Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.1 passage
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.1 passage
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.1 passage
• Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.1 passage
• Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.1 passage
• Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.1 passage
• Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study.1 passage
• Selective autophagy as a potential therapeutic target for neurodegenerative disorders.1 passage
• Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial.1 passage
• Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study.1 passage
• Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.1 passage
• Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.1 passage
• Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study.1 passage
• Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.1 passage
• Severe traumatic brain injury: targeted management in the intensive care unit.1 passage
• Sex differences in the epidemiology, clinical features, and pathophysiology of migraine.1 passage
• Sex differences in the evaluation and treatment of acute ischaemic stroke.1 passage
• Sleep disorders in autoimmune encephalitis.1 passage
• Sleep-wake disturbances after traumatic brain injury.1 passage
• Small vessel disease: mechanisms and clinical implications.1 passage
• Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.1 passage
• Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.1 passage
• Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.1 passage
• Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy.1 passage
• Status epilepticus in adults.1 passage
• Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis.1 passage
• Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial.1 passage
• Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts.1 passage
• Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.1 passage
• Stroke genetics: discovery, biology, and clinical applications.1 passage
• Stroke in China: advances and challenges in epidemiology, prevention, and management.1 passage
• Stroke-heart syndrome: clinical presentation and underlying mechanisms.1 passage
• Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.1 passage
• Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.1 passage
• Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention.1 passage
• Surgical treatment for epilepsy: the potential gap between evidence and practice.1 passage
• Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.1 passage
• Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study.1 passage
• Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.1 passage
• Tau imaging: early progress and future directions.1 passage
• Technological advances and changing indications for lumbar puncture in neurological disorders.1 passage
• Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.1 passage
• The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study.1 passage
• The characterisation of subjective cognitive decline.1 passage
• The chronic and evolving neurological consequences of traumatic brain injury.1 passage
• The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes.1 passage
• The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study.1 passage
• The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.1 passage
• The effects of socioeconomic status on stroke risk and outcomes.1 passage
• The epidemiology of Parkinson's disease: risk factors and prevention.1 passage
• The genetic architecture of Parkinson's disease.1 passage
• The genetic landscape of the epileptic encephalopathies of infancy and childhood.1 passage
• The global burden of neurological disorders: translating evidence into policy.1 passage
• The glymphatic pathway in neurological disorders.1 passage
• The gut microbiome in neurological disorders.1 passage
• The hippocampus in multiple sclerosis.1 passage
• The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data.1 passage
• The interface between delirium and dementia in elderly adults.1 passage
• The neurobiology, investigation, and treatment of chronic insomnia.1 passage
• The neurocritical care of tuberculous meningitis.1 passage
• The pathophysiology of migraine: implications for clinical management.1 passage
• The prion model for progression and diversity of neurodegenerative diseases.1 passage
• The prognosis of dementia with Lewy bodies.1 passage
• The promise of telemedicine for chronic neurological disorders: the example of Parkinson's disease.1 passage
• The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders.1 passage
• The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications.1 passage
• The role of diet in secondary stroke prevention.1 passage
• The role of manganese dysregulation in neurological disease: emerging evidence.1 passage
• The role of plasminogen activators in stroke treatment: fibrinolysis and beyond.1 passage
• The roles of surgery and technology in understanding focal epilepsy and its comorbidities.1 passage
• The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.1 passage
• The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.1 passage
• Therapeutic interventions in patients with prolonged disorders of consciousness.1 passage
• Therapies targeting DNA and RNA in Huntington's disease.1 passage
• Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study.1 passage
• Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.1 passage
• Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.1 passage
• Towards a treatment for genetic prion disease: trials and biomarkers.1 passage
• Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.1 passage
• Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study.1 passage
• Traumatic brain injury in China.1 passage
• Treating the whole body in Huntington's disease.1 passage
• Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.1 passage
• Treatment of progressive multiple sclerosis: what works, what does not, and what is needed.1 passage
• Ultra-rare genetic variation in common epilepsies: a case-control sequencing study.1 passage
• Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions.1 passage
• Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective.1 passage
• Use of brain diffusion tensor imaging for the prediction of long-term neurological outcomes in patients after cardiac arrest: a multicentre, international, prospective, observational, cohort study.1 passage
• Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies.1 passage
• Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug.1 passage
• Wilson's disease and other neurological copper disorders.1 passage
• β-adrenoreceptors and the risk of Parkinson's disease.1 passage